In February, the NIH announced it would lead a major research effort focused on identifying what causes prolonged COVID-19 symptoms and on the development of methods to treat or prevent the problems.
Francis Collins, MD, PhD, NIH director, said during an April 28 House Energy and Commerce subcommittee the agency is advancing the initial effort with an “unprecedented” large-scale study. Since the February announcement, the NIH has received 273 requests for research proposals, with comprehensive studies expected to start this summer, Dr. Collins said.
“Some of you have been suffering for more than a year, with no answers, no treatment options, not even a forecast of what your future may hold,” Dr. Collins said. “Some of you have even faced skepticism about whether your symptoms are real. I want to assure you we at NIH hear you and believe you.”
Preliminary research estimates anywhere from 10 percent to 30 percent of people with COVID-19 go on to become long-haulers, Dr. Collins said.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
